SCOPE Europe 2026

Program:
Clinical data strategy & AI innovation​
Wednesday,  October 14​, 2026 at 10:00 am

Overview:

Using artificial intelligence-driven risk prediction and CRA intervention to improve enrollment outcomes at clinical trial sites

Non-enrolling clinical trial sites increase costs, delay timelines, and strain resources, often identified only after issues emerge. In this session, Tim Mudric, Jr., vice president, clinical development strategic enablement, PPD clinical research business of Thermo Fisher Scientific introduces the non-enrolling site tool (NEST).

NEST is a machine learning–based predictive analytics platform that assesses site-level enrollment risk at pre-site initiation visit, activation and 60 days post-activation, using operational, site, investigator and real-time trial data to guide targeted clinical research associate interventions.